Intramuscular Injectable Suspensions - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511242099

Publication Date:

November 6, 2024

Pages:

116

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Intramuscular Injectable Suspensions was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Intramuscular Injectable Suspensions was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Intramuscular Injectable Suspensions was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Intramuscular Injectable Suspensions was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Intramuscular Injectable Suspensions include Merck Sharp & Dohme, Novo Nordisk, Lilly, Biocon Limited, Pfizer, BeiGene, EnteraBio, AbbVie and Pfizer Limited, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Intramuscular Injectable Suspensions, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Intramuscular Injectable Suspensions by region & country, by Type, and by Application.
The Intramuscular Injectable Suspensions market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intramuscular Injectable Suspensions.
麻豆原创 Segmentation
By Company
Merck Sharp & Dohme
Novo Nordisk
Lilly
Biocon Limited
Pfizer
BeiGene
EnteraBio
AbbVie
Pfizer Limited
Teva Pharmaceuticals USA
Bristol-Myers Squibb
Cipla
Baxter International
AstraZeneca
Segment by Type:
Single-Dose Injections
Multiple-Dose Injections
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Intramuscular Injectable Suspensions manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Intramuscular Injectable Suspensions in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Intramuscular Injectable Suspensions in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Intramuscular Injectable Suspensions Product Introduction
1.2 Global Intramuscular Injectable Suspensions 麻豆原创 Size Forecast
1.2.1 Global Intramuscular Injectable Suspensions Sales Value (2019-2030)
1.2.2 Global Intramuscular Injectable Suspensions Sales Volume (2019-2030)
1.2.3 Global Intramuscular Injectable Suspensions Sales Price (2019-2030)
1.3 Intramuscular Injectable Suspensions 麻豆原创 Trends & Drivers
1.3.1 Intramuscular Injectable Suspensions Industry Trends
1.3.2 Intramuscular Injectable Suspensions 麻豆原创 Drivers & Opportunity
1.3.3 Intramuscular Injectable Suspensions 麻豆原创 Challenges
1.3.4 Intramuscular Injectable Suspensions 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Intramuscular Injectable Suspensions Players Revenue Ranking (2023)
2.2 Global Intramuscular Injectable Suspensions Revenue by Company (2019-2024)
2.3 Global Intramuscular Injectable Suspensions Players Sales Volume Ranking (2023)
2.4 Global Intramuscular Injectable Suspensions Sales Volume by Company Players (2019-2024)
2.5 Global Intramuscular Injectable Suspensions Average Price by Company (2019-2024)
2.6 Key Manufacturers Intramuscular Injectable Suspensions Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Intramuscular Injectable Suspensions Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Intramuscular Injectable Suspensions
2.9 Intramuscular Injectable Suspensions 麻豆原创 Competitive Analysis
2.9.1 Intramuscular Injectable Suspensions 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Intramuscular Injectable Suspensions Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intramuscular Injectable Suspensions as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single-Dose Injections
3.1.2 Multiple-Dose Injections
3.2 Global Intramuscular Injectable Suspensions Sales Value by Type
3.2.1 Global Intramuscular Injectable Suspensions Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Intramuscular Injectable Suspensions Sales Value, by Type (2019-2030)
3.2.3 Global Intramuscular Injectable Suspensions Sales Value, by Type (%) (2019-2030)
3.3 Global Intramuscular Injectable Suspensions Sales Volume by Type
3.3.1 Global Intramuscular Injectable Suspensions Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Intramuscular Injectable Suspensions Sales Volume, by Type (2019-2030)
3.3.3 Global Intramuscular Injectable Suspensions Sales Volume, by Type (%) (2019-2030)
3.4 Global Intramuscular Injectable Suspensions Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Intramuscular Injectable Suspensions Sales Value by Application
4.2.1 Global Intramuscular Injectable Suspensions Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Intramuscular Injectable Suspensions Sales Value, by Application (2019-2030)
4.2.3 Global Intramuscular Injectable Suspensions Sales Value, by Application (%) (2019-2030)
4.3 Global Intramuscular Injectable Suspensions Sales Volume by Application
4.3.1 Global Intramuscular Injectable Suspensions Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Intramuscular Injectable Suspensions Sales Volume, by Application (2019-2030)
4.3.3 Global Intramuscular Injectable Suspensions Sales Volume, by Application (%) (2019-2030)
4.4 Global Intramuscular Injectable Suspensions Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Intramuscular Injectable Suspensions Sales Value by Region
5.1.1 Global Intramuscular Injectable Suspensions Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Intramuscular Injectable Suspensions Sales Value by Region (2019-2024)
5.1.3 Global Intramuscular Injectable Suspensions Sales Value by Region (2025-2030)
5.1.4 Global Intramuscular Injectable Suspensions Sales Value by Region (%), (2019-2030)
5.2 Global Intramuscular Injectable Suspensions Sales Volume by Region
5.2.1 Global Intramuscular Injectable Suspensions Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Intramuscular Injectable Suspensions Sales Volume by Region (2019-2024)
5.2.3 Global Intramuscular Injectable Suspensions Sales Volume by Region (2025-2030)
5.2.4 Global Intramuscular Injectable Suspensions Sales Volume by Region (%), (2019-2030)
5.3 Global Intramuscular Injectable Suspensions Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Intramuscular Injectable Suspensions Sales Value, 2019-2030
5.4.2 North America Intramuscular Injectable Suspensions Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Intramuscular Injectable Suspensions Sales Value, 2019-2030
5.5.2 Europe Intramuscular Injectable Suspensions Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Intramuscular Injectable Suspensions Sales Value, 2019-2030
5.6.2 Asia Pacific Intramuscular Injectable Suspensions Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Intramuscular Injectable Suspensions Sales Value, 2019-2030
5.7.2 South America Intramuscular Injectable Suspensions Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Intramuscular Injectable Suspensions Sales Value, 2019-2030
5.8.2 Middle East & Africa Intramuscular Injectable Suspensions Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Intramuscular Injectable Suspensions Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Intramuscular Injectable Suspensions Sales Value
6.2.1 Key Countries/Regions Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.2.2 Key Countries/Regions Intramuscular Injectable Suspensions Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.3.2 United States Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.4.2 Europe Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.5.2 China Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.5.3 China Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.6.2 Japan Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.7.2 South Korea Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.8.2 Southeast Asia Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Intramuscular Injectable Suspensions Sales Value, 2019-2030
6.9.2 India Intramuscular Injectable Suspensions Sales Value by Type (%), 2023 VS 2030
6.9.3 India Intramuscular Injectable Suspensions Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck Sharp & Dohme
7.1.1 Merck Sharp & Dohme Company Information
7.1.2 Merck Sharp & Dohme Introduction and Business Overview
7.1.3 Merck Sharp & Dohme Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Sharp & Dohme Intramuscular Injectable Suspensions Product Offerings
7.1.5 Merck Sharp & Dohme Recent Development
7.2 Novo Nordisk
7.2.1 Novo Nordisk Company Information
7.2.2 Novo Nordisk Introduction and Business Overview
7.2.3 Novo Nordisk Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novo Nordisk Intramuscular Injectable Suspensions Product Offerings
7.2.5 Novo Nordisk Recent Development
7.3 Lilly
7.3.1 Lilly Company Information
7.3.2 Lilly Introduction and Business Overview
7.3.3 Lilly Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Lilly Intramuscular Injectable Suspensions Product Offerings
7.3.5 Lilly Recent Development
7.4 Biocon Limited
7.4.1 Biocon Limited Company Information
7.4.2 Biocon Limited Introduction and Business Overview
7.4.3 Biocon Limited Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Biocon Limited Intramuscular Injectable Suspensions Product Offerings
7.4.5 Biocon Limited Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Information
7.5.2 Pfizer Introduction and Business Overview
7.5.3 Pfizer Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Pfizer Intramuscular Injectable Suspensions Product Offerings
7.5.5 Pfizer Recent Development
7.6 BeiGene
7.6.1 BeiGene Company Information
7.6.2 BeiGene Introduction and Business Overview
7.6.3 BeiGene Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.6.4 BeiGene Intramuscular Injectable Suspensions Product Offerings
7.6.5 BeiGene Recent Development
7.7 EnteraBio
7.7.1 EnteraBio Company Information
7.7.2 EnteraBio Introduction and Business Overview
7.7.3 EnteraBio Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.7.4 EnteraBio Intramuscular Injectable Suspensions Product Offerings
7.7.5 EnteraBio Recent Development
7.8 AbbVie
7.8.1 AbbVie Company Information
7.8.2 AbbVie Introduction and Business Overview
7.8.3 AbbVie Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.8.4 AbbVie Intramuscular Injectable Suspensions Product Offerings
7.8.5 AbbVie Recent Development
7.9 Pfizer Limited
7.9.1 Pfizer Limited Company Information
7.9.2 Pfizer Limited Introduction and Business Overview
7.9.3 Pfizer Limited Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Pfizer Limited Intramuscular Injectable Suspensions Product Offerings
7.9.5 Pfizer Limited Recent Development
7.10 Teva Pharmaceuticals USA
7.10.1 Teva Pharmaceuticals USA Company Information
7.10.2 Teva Pharmaceuticals USA Introduction and Business Overview
7.10.3 Teva Pharmaceuticals USA Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Teva Pharmaceuticals USA Intramuscular Injectable Suspensions Product Offerings
7.10.5 Teva Pharmaceuticals USA Recent Development
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Company Information
7.11.2 Bristol-Myers Squibb Introduction and Business Overview
7.11.3 Bristol-Myers Squibb Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Bristol-Myers Squibb Intramuscular Injectable Suspensions Product Offerings
7.11.5 Bristol-Myers Squibb Recent Development
7.12 Cipla
7.12.1 Cipla Company Information
7.12.2 Cipla Introduction and Business Overview
7.12.3 Cipla Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Cipla Intramuscular Injectable Suspensions Product Offerings
7.12.5 Cipla Recent Development
7.13 Baxter International
7.13.1 Baxter International Company Information
7.13.2 Baxter International Introduction and Business Overview
7.13.3 Baxter International Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Baxter International Intramuscular Injectable Suspensions Product Offerings
7.13.5 Baxter International Recent Development
7.14 AstraZeneca
7.14.1 AstraZeneca Company Information
7.14.2 AstraZeneca Introduction and Business Overview
7.14.3 AstraZeneca Intramuscular Injectable Suspensions Sales, Revenue and Gross Margin (2019-2024)
7.14.4 AstraZeneca Intramuscular Injectable Suspensions Product Offerings
7.14.5 AstraZeneca Recent Development
8 Industry Chain Analysis
8.1 Intramuscular Injectable Suspensions Industrial Chain
8.2 Intramuscular Injectable Suspensions Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Intramuscular Injectable Suspensions Sales Model
8.5.2 Sales Channel
8.5.3 Intramuscular Injectable Suspensions Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Merck Sharp & Dohme
Novo Nordisk
Lilly
Biocon Limited
Pfizer
BeiGene
EnteraBio
AbbVie
Pfizer Limited
Teva Pharmaceuticals USA
Bristol-Myers Squibb
Cipla
Baxter International
AstraZeneca

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.